Approved cell therapies have demonstrated success in treating hematological malignancies by targeting specific markers. However, this approach has proven ineffective in treating solid tumors due to the absence of tumor-associated antigens (TAAs) that can be targeted without harming normal tissue. Preclinical models currently in use do not accurately replicate TAA expression, thus hindering progress in therapeutic development. Patient-derived HUB Organoids provide a solution by preserving both patient heterogeneity and specific TAAs, which are critical factors for advancing cell therapies for solid tumors. Co-cultures of these organoids offer a valuable tool for investigating the targeting of tumors, the immune microenvironment, or both, in immunotherapeutic research.
To meet the growing demand for patient-derived models in immuno-oncology, HUB has prioritized the development of I-O biobanks, encompassing protocols for isolating and expanding various cell types, including tumor cells, fibroblasts, and T cells, to establish autologous and non-autologous systems.
Download our case study to gain in-depth insights into:
- The significance of PDOs in the development of immunotherapy drugs for solid tumors
- Scientific findings from two case studies illustrating the effectiveness of organoid-based immune cell co-cultures in assessing the efficacy and toxicity of IO agents
- An interview featuring our CSO, Dr. Sylvia Boj, and Dr. Andrea Bisso, the director of pharmacology at Gadeta*, addressing crucial questions for researchers interested in utilizing patient-derived organoids for immunotherapy drug development
*The following content was created in collaboration with Gadeta. We extend our gratitude for their contribution and expertise in developing this material